Physician profile
Stephen White
NPI 1265486229
$8,339.39
in general payments reported to CMS, 2019-2025
60 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $298 · 2021: $1,242 · 2022: $1,808 · 2023: $1,319 · 2024: $932 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $916.78 | 2019-2025 | |
| Amgen INC. | $754.59 | 2019-2023 | Kyprolis, Blincyto, Vectibix |
| Merck Sharp & Dohme LLC | $718.67 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $516.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.50 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $400.37 | 2019-2024 | Tagrisso, Lynparza |
| Genentech USA, INC. | $341.61 | 2019-2024 | Venclexta, Avastin, Rozlytrek |
| Janssen Biotech, INC. | $320.43 | 2020-2025 | Darzalex, Rybrevant, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $311.46 | 2019-2025 | Libtayo |
| Celgene Corporation | $225.76 | 2019-2023 | Pomalyst |
| Astellas Pharma US INC | $196.37 | 2019-2024 | Xtandi |
| Genzyme Corporation | $195.04 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.16 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Gilead Sciences, INC. | $185.17 | 2019-2025 | Trodelvy |
| Puma Biotechnology, INC. | $169.61 | 2019-2024 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.36 | 2019-2025 | Venclexta |
| Kite Pharma, INC. | $140.01 | 2021-2025 | Yescarta |
| Lilly USA, LLC | $135.28 | 2019-2025 | Verzenio, Jaypirca |
| Acrotech Biopharma INC. | $128.86 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $127.86 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Allergan, INC. | $119.56 | 2019 | |
| Daiichi Sankyo INC. | $119.37 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Pharmacyclics LLC, An Abbvie Company | $92.43 | 2019-2023 | Imbruvica |
| Taiho Oncology, INC. | $92.13 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.36 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $77.07 | 2021-2022 | |
| Eisai INC. | $75.28 | 2020-2025 | |
| Incyte Corporation | $73.72 | 2019-2021 | |
| Beigene USA, INC. | $70.97 | 2022-2024 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.68 | 2022-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $65.52 | 2022-2024 | |
| Seagen INC. | $61.93 | 2021-2022 | |
| Sobi, INC | $60.86 | 2025 | |
| Ferring Pharmaceuticals INC. | $60.72 | 2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $60.49 | 2020-2024 | Somatuline Depot, Onivyde |
| G1 Therapeutics, INC. | $55.62 | 2022-2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $50.76 | 2022-2023 | Fotivda |
| Csl Behring | $38.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.77 | 2019-2021 | |
| Kyowa Kirin, INC. | $35.73 | 2019 | |
| Array Biopharma INC | $34.81 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Brainlab, INC. | $28.87 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Morphosys, US INC. | $27.91 | 2022-2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $27.09 | 2022 | |
| Global Blood Therapeutics, INC. | $26.85 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $24.75 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.46 | 2024 | Givlaari |
| Convatec INC. | $19.78 | 2019 | |
| Octapharma USA, INC. | $18.60 | 2023 | Octagam Immune Globulin (Human) |
| Cti Biopharma Corp. | $18.55 | 2023 | Vonjo |
| Ge Healthcare | $17.62 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.18 | 2019 | |
| Servier Pharmaceuticals LLC | $14.59 | 2023 | |
| Medtronic, INC. | $14.41 | 2021 | |
| Glaxosmithkline, LLC. | $14.22 | 2022 | |
| Springworks Therapeutics, INC. | $14.07 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $13.70 | 2024 | |
| Deciphera Pharmaceuticals INC. | $11.36 | 2021 | |
| Exelixis INC. | $11.15 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.